AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$RVMD

GOLDSMITH MARK A sold $1.3M of RVMD (indirect holdings)

GOLDSMITH MARK A (See Remarks) sold 6,000 indirectly-held shares of Revolution Medicines, Inc. (RVMD) at an average of $209.20 ($207.25–$212.06, $1.26M total) across 12 trades on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GOLDSMITH MARK A
Published Aug 25, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RVMD
Bearish
medium confidence
Mentioned
$RVMD
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which traders may incorporate into short‑term positioning.

02

Market read

Insider sale of $1.3 M in RVMD may influence short‑term price action and sentiment in the biotech sector.

03

What to watch

Upcoming clinical trial data could offset any negative perception from the sale.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑08‑21

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources of corporate insider activity.

Company-level read

Ticker impact

$RVMDBearishMedium confidence
Context

Officer Mark Goldsmith sold 6,000 RVMD shares for $1.3M under a 10b5‑1 plan on 2026‑08‑21.

Expected impact

Potential modest downside of 2‑4% over the next few days.

Evidence & confidence

The sale size (~$1.3M) is material for a mid‑cap biotech and was executed via a pre‑arranged plan, suggesting a neutral to slightly bearish impact.

Market effects

Sector

May raise concerns among biotech investors about insider sentiment.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact; primarily relevant to RVMD shareholders.

Counterpoint

What could challenge this read

The 10b5‑1 plan could be routine liquidity management, not a bearish signal.

Key entities

  • Company
    Revolution Medicines, Inc.

    Biotech firm listed on NASDAQ under ticker RVMD.

  • Officer
    Mark Goldsmith

    Director/officer of Revolution Medicines who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RVMD insider trading history →

Related articles

SEP 4
$RVMDHighAI 8/10

Michael Osterholm Says He's Staying Four More Years as Public Health's Systems Buckle — BigGo Finance

Revolution Medicines' FDA-approved cancer drug, divarasib and razabi, targets RAS protein, previously deemed undruggable. CEO Mark Goldsmith bet the company on this target, leading to a successful Phase 3 trial. Michael Osterholm, 73, delayed retirement to address public health challenges, launching the Vaccine Integrity Project. David Baker, Nobel laureate, focuses on designing novel proteins and mentoring scientists.

finance.biggo.com2 min
SEP 3
$RVMDHighAI 9/10

Daraxonrasib shrinks tumours in one-third of lung cancer patients

Revolution Medicines Inc. (RVMD) reported that its experimental drug daraxonrasib shrank tumors in 33% of advanced lung cancer patients in a Phase 1/2 trial, with symptom improvements. The study, published in the New England Journal of Medicine, involved 136 patients with RAS gene mutations. The drug targets multiple RAS mutations and showed a median response duration of 11.5 months. Side effects were common, with rash, diarrhea, and nausea affecting many patients. The company is now conducting

mugglehead.com2 min
SEP 3
$RVMDMedAI 8/10

RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer

Revolution Medicines (RVMD) presented updated Phase 1/2 trial data for Rasonque in non-small cell lung cancer (NSCLC), showing a 42% overall response rate, 8.3-month median progression-free survival, and 16-month median overall survival. Truist Securities noted the results support RVMD's Phase 3 lung cancer study. Rasonque was recently FDA-approved for pancreatic cancer, with Phase 3 results expected in December 2027 for NSCLC.

biospace.com2 min
SEP 3
$RVMDMedAI 8/10

NEJM publishes daraxonrasib NSCLC data supporting Phase III program

Revolution Medicines (RVMD) published Phase I/II data in NEJM showing daraxonrasib's antitumor activity in RAS-mutant NSCLC. The study reported a 42% response rate and 8.3-month median progression-free survival. The company is advancing the drug in a Phase III trial. Daraxonrasib was recently approved for pancreatic cancer, marking the company's first commercial product.

allsci.com2 min
SEP 2
$RVMDMedAI 9/10

RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM

Revolution Medicines (RVMD) announced the publication of Phase 1/2 trial results for RASONQUE in the New England Journal of Medicine. The data showed promising efficacy and safety in treating advanced RAS mutant NSCLC. The company has a market cap of $44.85 billion and is currently unprofitable, with a high Price-to-Sales ratio of 70.5x. Insider activity shows significant selling, while guru ownership trends are mixed.

gurufocus.com3 min